XLO news

Latest 1 stories · newest Nov 10, 2026

XLO

Xilio Doses First Patient in Phase 1/2 XTX501 Trial

Xilio Therapeutics dosed the first patient in a Phase 1/2 study for its PD-1 and masked IL-2 bispecific, with data expected in late 2027, highlighting further progress in its immuno-oncology pipeline.

Earnings|R&D Nov 10, 2026 sentiment +0.20 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same XLO feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/XLO/newsSTART FREE